Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug
Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies …

Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising
approach for cancer therapy with an expectation of no significant side effects. In the human …

The ability to generate T cells from pluripotent stem cells (PSCs) has the potential to
transform autologous T cell immunotherapy by facilitating universal, off-the-shelf cell …

Studies of human T cell development require robust model systems that recapitulate the full
span of thymopoiesis, from hematopoietic stem and progenitor cells (HSPCs) through to …

The human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte (CTL) response is
critical in controlling HIV infection. Since the immune response does not eliminate HIV, it …

The proliferation and trafficking of T lymphocytes in immune responses are crucial events in
determining inflammatory responses. To study whole-body T lymphocyte dynamics …

Engineering stem cells presents an attractive paradigm for cancer immunotherapy. Stem
cells engineered to stably express various chimeric antigen receptors (CARs) or T-cell …

Realizing the clinical promise of cancer immunotherapy is hindered by gaps in our
knowledge of in vivo mechanisms underlying treatment response as well as treatment …

Hematopoietic stem cells (HSC s) provide an attractive target for immunotherapy of cancer
and leukemia by the introduction of genes encoding T‐cell receptors (TCR s) or chimeric …

Due to the durability and persistence of reservoirs of HIV-1-infected cells, combination
antiretroviral therapy (ART) is insufficient in eradicating infection. Achieving HIV-1 cure or …